Michael Niggel

At the upcoming American College of Rheumatology annual meeting ACR Convergence 2026, the Lupus Research Alliance and clinical affiliate Lupus Therapeutics will present new research findings focused on expanding access to research, deepening our understanding of the disease, and accelerating the path to new therapies. Presentations include 20+ abstracts involving the work of investigators from … Lupus Research Alliance to Showcase Scientific Advances Across the Research Continuum at ACR Convergence 2026

Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of a groundbreaking initiative by Lupus Therapeutics (LT), the clinical research affiliate of the Lupus Research Alliance (LRA), called IDEAL (Investigate Dietary Approaches for Lupus). IDEAL will provide up to two grants for pilot clinical studies evaluating … An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the Lupus … ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis